



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**April 9, 2013 6:00 – 8:30 p.m.**  
**\*\*Note Rescheduled Date\*\***

- 1. Executive Session** **6:00 - 6:30**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
  
- 2. Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**  
(Public Comment Prior to Board Action)
  
- 3. DVHA Pharmacy Administration Updates** **6:35 - 6:45**
  - Updates
  - Center for Evidence Based Policy Update
  
- 4. Medical Director Update** **6:45 - 6:45**
  - Clinical Programs Update
  - Prescriber Comments
  
- 5. Follow-up Items from Previous Meetings** **6:45 - 7:05**
  - Methadone for Chronic Pain
  - Suboxone<sup>®</sup> Tablet to Film Transition
  
- 6. RetroDUR/DUR** **7:05 – 7:30**
  - Benzodiazepines
  - Xyrem<sup>®</sup> (sodium oxybate)
  
- 7. Clinical Update: Drug Reviews** **7:30 – 7:40**  
(Public comment prior to Board action)
  - Abbreviated New Drug Reviews**
    - Episil<sup>®</sup> (wound barrier) Mouth/Throat Protectant
  
  - Full New Drug Reviews**
    - Aubagio<sup>®</sup> (teriflunomide) Oral Tablets

- 8. Therapeutic Drug Classes – Periodic Review** **7:40 – 8:15**  
(Public comment prior to Board action)  
**Class review documents available on DVHA web site 04/09/2013 @ 12 Noon**
- Bone Resorption Inhibitors
  - Dermatological Agents: Immunomodulators
  - Estrogens: Vaginal
  - Gastrointestinal: Inflammatory Bowel Agents
  - Growth Hormones
  - Ophthalmics: Antihistamines
  - Ophthalmics: Beta Blockers
  - Ophthalmics: Mast Cell Stabilizers
  - Ophthalmics: Miotics
  - Ophthalmics: NSAIDs
  - Ophthalmics: Prostaglandin Analogs
- 9. New Managed Therapeutic Drug Classes** **8:15 – 8:15**  
(Public comment prior to Board action)
- None
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:15 – 8:20**  
(Public comment prior to Board action)
- Lipotropics: Miscellaneous/Combinations
- 11. General Announcements** **8:20– 8:30**  
**Selected FDA Safety Alerts**
- Azithromycin - risk of potentially fatal heart rhythms
  - Clinical Specialties Compounding Pharmacy – Recall All Lots Sterile Products
  - Incretin Mimetic Drugs - possible increased risk of pancreatitis and pre-cancerous findings of the pancreas
  - Omontys<sup>®</sup> – Serious Hypersensitivity Reactions
  - One Touch Verio<sup>®</sup> IQ Blood Glucose Meters – turn off at extremely high blood glucose levels
- 12. Adjourn** **8:30**